Dr. Yuntao Zhang (right), Vice President of the CNBG, shakes hands with Dr. Jerome Kim (left), Director-General of IVI, as they exchange an MOU
September 23, 2019, SEOUL, Korea — On September 9, 2019, the China National Biotec Group (CNBG) and the International Vaccine Institute (IVI) held a meeting at the Hongqiao Office of Shanghai Institute of Biological Products (SIBP) and signed a memorandum of understanding.
CNBG’s Vice President, Dr. Yuntao Zhang, and Dr. Jerome Kim, Director General of IVI, both delivered opening speeches, expressing their wishes and expectations for the forthcoming cooperation between the two parties. During the meeting, the two parties identified specific areas of collaboration: typhoid conjugate vaccine, rotavirus vaccine and monoclonal antibody. The parties will combine forces on R&D and clinical activities on these subjects and jointly fulfill the mission of providing high-quality vaccines to developing countries. In addition, the two sides exchanged information and formulated the main objectives and work plan for the next phase.
An agreement has been reached that CNBG will play an increasingly important role in the future global public health. “To better address future challenges, IVI is willing to actively assist CNBG in R&D, clinical and other areas, Dr. Yuntao Zhang said. “The parties will adhere to the spirit of the meeting, cooperate wholeheartedly, actively implement projects, and make unremitting efforts for the common vision of global health.”
Dr. Jerome Kim said, “IVI is excited to partner with CNBG, the largest state-owned bio-pharmaceutical company in China. We look forward to close collaboration with CNBG in R&D, clinical development and vaccine introduction to bring some of CNBG’s high-quality vaccines to people who need them the most in developing countries and fulfill our shared mission of saving and protecting lives from infectious diseases.”
The meeting was presided over by Dr. Yuntao Zhang, vice president of CNBG, and attended by more than 40 participants from the International Cooperation Department of CNBG, the project members of the subsidiary companies and IVI
About the China National Biotec Group
China National Biotec Group is dedicated in the field of healthcare since 1919. It is the largest state-owned bio-pharmaceutical company in China in terms of product portfolio, production capacity and company scope. It has 6 business segments including human vaccines, blood products, animal health, medical aesthetics, diagnostics and biotherapeutics. CNBG is capable to produce 50 kinds of human vaccines against 15 infectious diseases. The annual capacity could read up to 700 millions doses. It is the major supplier to the Chinese EPI program, supplying over 80% vaccines. It is also the largest blood producer in China with 1400 tons of plasma collection capability. It is the only botulinum toxin producer in China and the first Chinese company pre-qualified by the WHO. CNBG currently owns 1 innovative vaccine R&D center, 7 human vaccines manufacture sites, 2 animal vaccine manufacture sites, 1 diagnostic company and 1 public listed company for plasma derived products. CNBG has more than 10,000 employees. The total asset has reached 3.6billion USD in 2018 while the total revenue has reached 1.6billion USD.
About The International Vaccine Institute
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries throughout Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, Group A Strep, and Schistosomiasis, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int